Too much, too little, or none at all : dealing with substandard and fake drugs
| Errataetall: |
CommentOn: Lancet. 2001 Jun 16;357(9272):1933-6. - PMID 11425415 |
|---|---|
| Medienart: |
Artikel |
| Erscheinungsjahr: |
2001 |
|---|---|
| Erschienen: |
2001 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:357 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 357(2001), 9272 vom: 16. Juni, Seite 1904 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wan Po, A L [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 12.07.2001 Date Revised 11.06.2019 published: Print CommentOn: Lancet. 2001 Jun 16;357(9272):1933-6. - PMID 11425415 Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM113289618 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM113289618 | ||
| 003 | DE-627 | ||
| 005 | 20231222163543.0 | ||
| 007 | tu | ||
| 008 | 231222s2001 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0378.xml |
| 035 | |a (DE-627)NLM113289618 | ||
| 035 | |a (NLM)11425409 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wan Po, A L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Too much, too little, or none at all |b dealing with substandard and fake drugs |
| 264 | 1 | |c 2001 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2001 | ||
| 500 | |a Date Revised 11.06.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Lancet. 2001 Jun 16;357(9272):1933-6. - PMID 11425415 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Immunoglobulin Fab Fragments |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Platelet Glycoprotein GPIIb-IIIa Complex |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a reteplase |2 NLM | |
| 650 | 7 | |a DQA630RIE9 |2 NLM | |
| 650 | 7 | |a Tissue Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.68 |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 650 | 7 | |a Abciximab |2 NLM | |
| 650 | 7 | |a X85G7936GV |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 357(2001), 9272 vom: 16. Juni, Seite 1904 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:357 |g year:2001 |g number:9272 |g day:16 |g month:06 |g pages:1904 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 357 |j 2001 |e 9272 |b 16 |c 06 |h 1904 | ||